Skip to content

LUCAID: Agentic Multimodal AI for Lung Cancer Precision Pathology

Aug 2026 · 0 citations
Computer Science

TL;DR

LUCAID is an agentic AI system for precision lung cancer pathology that combines diagnostic reasoning with nine modules that cover the full routine workflow, from quality control, tumor detection and segmentation, histological subtyping, tumor microenvironment profiling, tumor cellularity quantification, and predictive biomarker scoring to automated structured report generation.

Abstract

Lung cancer tissue diagnostics is complex, as therapy decisions in precision oncology rely on the integration of histomorphological, immunohistochemical, and molecular features. Yet pathological assessment remains largely visual and semi-quantitative and shows interobserver variability, while existing artificial intelligence (AI) tools cover only selected tasks, rarely reach generalizable expert-level performance, and lack prospective clinical validation. To address these challenges, we developed and clinically validated LUCAID, an agentic AI system for precision lung cancer pathology. An integrative agent couples diagnostic reasoning with nine modules that cover the full routine workflow, from quality control, tumor detection and segmentation, histological subtyping, tumor microenvironment profiling, tumor cellularity quantification, and predictive biomarker scoring (PD-L1, MET, TROP-2) to automated structured report generation. LUCAID enables users to interactively query the module outputs and generate reports that contextualize the results. Against large-scale expert ground-truth annotations, the analysis modules achieved F1 scores of 0.82-0.95. In prospective clinical validation, LUCAID reached 93.0% concordance with an expert-panel adjudicated reference standard across clinically actionable decisions, compared with 68.3-81.1% for five experienced thoracic pathologists.

View source

Similar papers

Open access Aug 2026

Explainable AI-Derived Spatial Pathological Features of Tumor, Necrosis, and Lymphocytes Identify Key Histological Signatures for Residual Cancer Burden Assessment in Breast Cancer

Background: Conventional histopathological assessment of residual cancer burden (RCB) following neoadjuvant therapy for breast cancer relies on manual visual evaluation, lacking objective quantification of spatial interactions among tumor, necrosis, and lymphocyte compartments. This limits prognostic accuracy and imped...

Xin Shu, Fan Wang, Tian-Cheng Zhao et al. · 0 citations
#federated learning Review Open access Sep 2026

Artificial intelligence and radiomics in lung cancer: from imaging to clinical care

Artificial intelligence (AI) and radiomics have emerged as promising approaches in lung-cancer imaging by extracting quantitative features from routine medical images beyond visual assessment alone. Proof-of-concept studies span pulmonary nodule characterisation, molecular biomarker prediction, treatment-response asses...

J. Naidu, V. Baskaradoss · 0 citations
#explainable ai Review Open access Sep 2026

Artificial intelligence in non-small cell lung cancer: transforming diagnosis, treatment, and prognostic evaluation

Non-small cell lung cancer (NSCLC) is characterized by profound biological heterogeneity, frequently leading to late-stage diagnosis, recurrence, or metastasis. Conventional clinical pathways heavily depend on subjective visual interpretations, invasive tissue biopsies, and experience-based medical models that constrai...

Shuai-Yu Zheng, Chi Lv, Zhen Yao · 0 citations
Open access Oct 2026

Knowledge-guided Multimodal Learning for Interpretable Prediction of Pathological Complete Response and Survival in Breast Cancer.

PURPOSE Pretreatment estimation of pathological complete response (pCR) to neoadjuvant chemotherapy may support risk stratification and future response-adapted clinical studies in breast cancer. However, existing deep learning approaches often rely on "black-box" visual pattern recognition, suffering from poor interpre...

Wen-Chuan Zhang, Shu-Wan Zhang, Ya-Ni Wei et al. · 0 citations
#graph neural networks Review Open access Sep 2026

Multimodal Artificial Intelligence in Lung Cancer: From Data Integration to Precision Oncology

Current AI applications in lung cancer related to radiologic imaging, digital pathology, genomics, immunohistochemistry, and Cell Painting morphology are examined and their potential to be incorporated into a proposed multimodal model is examined.

T. Chakrabarti, A. Mansour, Xi-Wei Wu et al. · 0 citations
Review Open access Sep 2026

AI Agents for Multimodal Oncology Diagnosis: Toward Transparent and Traceable Clinical Decision Support

This Viewpoint defines an AI agent as a feedback-driven system that maintains task state, selects among governed tools, observes results, and revises its plan under explicit safety constraints, and separates agents from multimodal foundation models, retrieval-augmented generation, and fixed workflow automation.

Liu-Yang Yang, Liyu Shan, Xiang-Mei Yao et al. · 0 citations

Related blog posts

MIT News · Artificial Intelligence Sep 29, 2026

Who we become when we talk to machines

Professor Sherry Turkle’s new book, “Artificial Intimacy,” offers a withering critique of chatbots and the antisocial dynamics she believes they encourage.

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.